Inogen expects single digit growth for Q4, full year 2025
By HME News Staff
Updated 10:21 AM CST, Mon January 12, 2026
GOLETA, Calif. - Inogen estimates preliminary, unaudited total revenue of about $82 million for the fourth quarter of 2025, representing year-over-year growth of about 2%. Full-year 2025 revenue is expected to be about $349 million, about 4% year-over-year growth, with positive adjusted EBITDA. “While fourth quarter results continued to reflect strong performance in our business-to-business channels, we experienced a shift in the timing of a few large customer orders into the first half of 2026,” said Kevin Smith, president and CEO. “Although this delay relative to expectations is disappointing, our full-year results continued to make meaningful progress in executing our business turnaround. Highlights for the full year include positive revenue growth, advancing toward profitability, and expanding the innovation pipeline with launches of the Voxi 5 stationary oxygen concentrator and Aurora Masks for obstructive sleep apnea patients in the U.S. The Inogen team remains confident in our ability to drive growth acceleration and profitability into 2026, and we look forward to sharing additional details and 2026 financial guidance during our February earnings call.” Inogen will host a conference call on Feb. 24 to discuss its Q4 financial results.
-
Related: Inogen adds ‘innovation’ to CPAP market.
Comments